CVRx Inc
NASDAQ:CVRX
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
6.49
33.01
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one CVRX stock under the Base Case scenario is 12.77 USD. Compared to the current market price of 15.05 USD, CVRx Inc is Overvalued by 15%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
CVRx Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for CVRX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
CVRx Inc
Balance Sheet Decomposition
CVRx Inc
Current Assets | 123.9m |
Cash & Short-Term Investments | 100.2m |
Receivables | 9m |
Other Current Assets | 14.7m |
Non-Current Assets | 3.8m |
PP&E | 3.8m |
Other Non-Current Assets | 26k |
Current Liabilities | 10.9m |
Accounts Payable | 3.3m |
Accrued Liabilities | 7.7m |
Non-Current Liabilities | 51.5m |
Long-Term Debt | 49.2m |
Other Non-Current Liabilities | 2.3m |
Earnings Waterfall
CVRx Inc
Revenue
|
47.3m
USD
|
Cost of Revenue
|
-7.5m
USD
|
Gross Profit
|
39.8m
USD
|
Operating Expenses
|
-98.6m
USD
|
Operating Income
|
-58.9m
USD
|
Other Expenses
|
400k
USD
|
Net Income
|
-58.5m
USD
|
Free Cash Flow Analysis
CVRx Inc
USD | |
Free Cash Flow | USD |
CVRX Profitability Score
Profitability Due Diligence
CVRx Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
CVRx Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
CVRX Solvency Score
Solvency Due Diligence
CVRx Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Score
CVRx Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CVRX Price Targets Summary
CVRx Inc
According to Wall Street analysts, the average 1-year price target for CVRX is 14.08 USD with a low forecast of 12.12 USD and a high forecast of 15.75 USD.
Dividends
Current shareholder yield for CVRX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
CVRX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
CVRx, Inc. develops proprietary active implantable technology to treat high blood pressure and heart failure. The company is headquartered in Minneapolis, Minnesota and currently employs 109 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing, manufacturing and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its platform technology offers BAROSTIM, designed to control the brain to address the imbalance of the autonomic nervous system (ANS), which causes heart failure (HF) and other cardiovascular diseases. The Company’s product, BAROSTIM NEO, is a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction (HFrEF). BAROSTIM NEO provides baroreflex activation therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. BAROSTIM NEO consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead.
Contact
IPO
Employees
Officers
The intrinsic value of one CVRX stock under the Base Case scenario is 12.77 USD.
Compared to the current market price of 15.05 USD, CVRx Inc is Overvalued by 15%.